Adipotide: Molecular Structure

Molecular Structure and Properties#

Adipotide (FTPP) is a chimeric peptidomimetic compound with a molecular weight of approximately 2,460 Da. It consists of two functional domains connected by a glycine-glycine linker, creating a bifunctional molecule designed for targeted vascular destruction in adipose tissue.

Structural Components#

Homing Domain: CKGGRAKDC#

The N-terminal homing domain is a 9-amino-acid cyclic peptide with the sequence Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys. The two terminal cysteine residues form an intramolecular disulfide bond, creating the cyclic conformation essential for receptor binding. This motif was isolated through in vivo phage display, a screening technique that uses bacteriophage libraries to identify peptides with affinity for specific vascular beds in living organisms.

The cyclic structure provides enhanced binding stability compared to linear peptides and confers some resistance to proteolytic degradation. The peptide recognizes and binds to prohibitin, a multifunctional protein that is differentially expressed on the surface of endothelial cells in white adipose tissue vasculature.

Linker Region: Gly-Gly#

The two glycine residues serve as a flexible spacer between the homing and effector domains. This short, conformationally flexible linker allows both domains to adopt their functional conformations independently while maintaining their physical connection as a single molecular entity.

Proapoptotic Domain: D(KLAKLAK)2#

The C-terminal effector domain is the repeated sequence Lys-Leu-Ala-Lys-Leu-Ala-Lys synthesized using D-amino acids (the mirror-image enantiomers of naturally occurring L-amino acids). This amphipathic peptide adopts an alpha-helical conformation with one face being hydrophobic and the other positively charged.

The use of D-amino acids is a critical design feature. D-peptides are resistant to degradation by natural proteases, which recognize L-amino acid substrates. This resistance extends the functional lifetime of the proapoptotic domain and ensures it remains active after receptor-mediated endocytosis delivers the compound into target cells.

Physicochemical Properties#

Receptor Binding#

The CKGGRAKDC motif binds to a receptor complex on adipose vasculature endothelium comprising prohibitin and Annexin A2 (ANXA2). Prohibitin is a mitochondrial chaperone protein that is also expressed on the cell surface, where it serves as a receptor for the CKGGRAKDC homing peptide. In the context of white adipose tissue, prohibitin is selectively expressed on the vascular endothelium, providing the basis for tissue-specific targeting.

The binding interaction is thought to involve both electrostatic and hydrophobic contacts between the cyclic peptide and the prohibitin-ANXA2 complex. Following binding, the compound undergoes receptor-mediated endocytosis, delivering the proapoptotic domain to the intracellular compartment.

Mechanism of Membrane Disruption#

Once internalized, the D(KLAKLAK)2 domain interacts with mitochondrial membranes. The amphipathic nature of the peptide allows it to insert into lipid bilayers, with the hydrophobic face embedding in the membrane and the charged lysine residues remaining exposed. This insertion disrupts the integrity of mitochondrial membranes, leading to loss of mitochondrial membrane potential, release of cytochrome c, and activation of the intrinsic apoptotic cascade.

The specificity of this domain for mitochondrial membranes over plasma membranes is attributed to the unique lipid composition of mitochondrial inner membranes, which are enriched in cardiolipin and have a higher negative charge density compared to other cellular membranes.

Pharmacokinetic Considerations#

Absorption and Distribution#

In animal studies, adipotide has been administered via intraperitoneal and subcutaneous routes. The compound distributes preferentially to adipose tissue vasculature due to the homing domain, though some distribution to renal vasculature has been observed, contributing to the noted nephrotoxicity.

Metabolism and Elimination#

The D-enantiomer effector domain is resistant to standard proteolytic degradation, while the L-amino acid homing domain is susceptible to normal peptide metabolism. The overall pharmacokinetic profile has not been precisely characterized in published literature, as most studies focus on the pharmacodynamic outcomes rather than detailed PK parameters.

Stability Considerations#

The disulfide bond in the cyclic homing domain is sensitive to reducing environments. In vitro stability requires appropriate buffering and avoidance of reducing agents. The D-peptide effector domain provides inherent stability against enzymatic degradation, giving the compound a functional advantage over purely L-peptide constructs.

Formulation and Administration#

In preclinical studies, adipotide was typically dissolved in sterile saline and administered via intraperitoneal injection in mice or subcutaneous injection in primates. No formal pharmaceutical formulation has been developed for clinical use. The compound requires standard peptide handling precautions, including storage at low temperatures and protection from repeated freeze-thaw cycles.

Related Reading#

• Adipotide overview and research guide
• Peptides similar to Adipotide
• Adipotide research evidence